WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including Levothyroxine Sodium Tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.
Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6), Drug Interactions (7.7), and Overdosage (10)]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning Thyroid hormones, including Levothyroxine Sodium Tablets should not be used for the treatment of obesity or for weight loss.
Doses beyond the range of daily hormonal requirements may produce serious or even life threatening manifestations of toxicity (6, 10).
Use: Labeled indications
- Hypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic)…
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Hypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Limitations of Use Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions (5.1)]. Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
(1) Limitations of Use Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis
Contraindications
4 CONTRAINDICATIONS Levothyroxine Sodium Tablets are contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.4)]. Uncorrected adrenal insufficiency (4)
US FDA labelDosing: Adult
- Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast. (2.1)
- Administer at least 4 hours before or after drugs that are known to interfere with absorption. (2.1)
- Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. (2.1)
- Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medications. Peak therapeutic effect may not be attained for 4-6 weeks. (2.2)
- See full prescribing information for dosing in specific patient populations. (2.3)
- Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. (2.4)
2.1 Important Administration Instructions
2.1 Important Administration Instructions Administer Levothyroxine Sodium Tablets as a single daily dose, on an empty stomach, one-half to one hour before breakfast. Administer Levothyroxine Sodium Tablets at least 4 hours before or after drugs known to interfere with Levothyroxine Sodium Tablets absorption [see Drug Interactions (7.1)].
Evaluate the need for dosage adjustments when regularly administering within one hour of certain foods that may affect Levothyroxine Sodium Tablets absorption [see Dosage and Administration (2.2 and 2.3), Drug Interactions (7.9) and Clinical Pharmacology (12.3)]. Administer Levothyroxine Sodium Tablets to pediatric patients who cannot swallow intact tablets by crushing the tablet, suspending the freshly crushed tablet in a small amount (5 to 10 mL) of water and immediately administering the suspension by spoon or dropper.
Ensure the patient ingests the full amount of the suspension. Do not store the suspension. Do not administer in foods that decrease absorption of Levothyroxine Sodium Tablets, such as soybean-based infant formula [see Drug Interactions (7.9)].
2.2 Important Considerations for Dosing
2.2 Important Considerations for Dosing The dosage of Levothyroxine Sodium Tablets for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated [see Dosage and Administration (2.3), Warnings and Precautions (5), and Drug Interactions (7)]. Dosing must be individualized to account for these factors and dosage adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration (2.4)].
For adult patients with primary hypothyroidism, titrate until the patient is clinically euthyroid and the serum TSH returns to normal [see Dosage and Administration (2.3)]. For secondary or tertiary hypothyroidism, serum TSH is not a reliable measure of Levothyroxine Sodium Tablets dosage adequacy and should not be used to monitor therapy.
Use the serum free-T4 level to titrate Levothyroxine Sodium Tablets dosing until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range [see Dosage and Administration (2.3)]. The peak therapeutic effect of a given dose of Levothyroxine Sodium Tablets may not be attained for 4 to 6 weeks.
2.3 Recommended Dosage and Titration Primary, Secondary, and Tertiary Hypothyroidism in Adults
2.3 Recommended Dosage and Titration Primary, Secondary, and Tertiary Hypothyroidism in Adults The recommended starting daily dosage of Levothyroxine Sodium Tablets in adults with primary, secondary, or tertiary hypothyroidism is based on age and comorbid cardiac conditions, as described in Table 1. For patients at risk of atrial fibrillation or patients with underlying cardiac disease, start with a lower dosage and titrate the dosage more slowly to avoid exacerbation of cardiac symptoms.
Dosage titration is based on serum TSH or free-T4 [see Dosage and Administration (2.2)]. Table 1. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Adults* Patient Population Starting Dosage Dosage Titration Based on Serum TSH or Free-T4 Adults diagnosed with hypothyroidism Full replacement dose is 1.6 mcg/kg/day.
Some patients require a lower starting dose. Titrate dosage by 12.5 to 25 mcg increments every 4 to 6 weeks, as needed until the patient is euthyroid. Adults at risk for atrial fibrillation or with underlying cardiac disease Lower starting dose (less than 1.6 mcg/kg/day) Titrate dosage every 6 to 8 weeks, as needed until the patient is euthyroid.
Geriatric patients Lower starting dose (less than 1.6 mcg/kg/day) *Dosages greater than 200 mcg/day are seldom required. An inadequate response to daily dosages greater than 300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors [see Dosage and Administration (2.1) and Drug Interactions (7)].
Primary, Secondary, and Tertiary Hypothyroidism in Pediatric Patients The recommended starting daily dosage of Levothyroxine Sodium Tablets in pediatric patients with primary, secondary, or tertiary hypothyroidism is based on body weight and changes with age as described in Table 2. Titrate the dosage (every 2 weeks) as needed based on serum TSH or free-T4 until the patient is euthyroid [see Dosage and Administration (2.2)].
Table 2. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Pediatric Patients Age Starting Daily Dosage Per Kg Body Weight * 0-3 months 10-15 mcg/kg/day 3-6 months 8-10 mcg/kg/day 6-12 months 6-8 mcg/kg/day 1-5 years 5-6 mcg/kg/day 6-12 years 4-5 mcg/kg/day Greater than 12 years but growth and puberty incomplete 2-3 mcg/kg/day Growth and puberty complete 1.6 mcg/kg/day *Adjust dosage based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4)].
Pediatric Patients from Birth to 3 Months of Age at Risk for Cardiac Failure Start at a lower starting dosage and increase the dosage every 4 to 6 weeks as needed based on clinical and laboratory response. Pediatric Patients at Risk for Hyperactivity To minimize the risk of hyperactivity, start at one-fourth the recommended full replacement dosage, and increase on a weekly basis by one-fourth the full recommended replacement dosage until the full recommended replacement dosage is reached.
Hypothyroidism in Pregnant Patients For pregnant patients with pre-existing hypothyroidism, measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at minimum, during each trimester of pregnancy. In pregnant patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. The recommended daily dosage of Levothyroxine Sodium Tablets in pregnant patients is described in Table 3.
Table 3. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Pregnant Patients Patient Population Starting Dosage Dose Adjustment and Titration Pre-existing primary hypothyroidism with serum TSH above normal trimester-specific range Pre-pregnancy dosage may increase during pregnancy Increase Levothyroxine Sodium Tablets dosage by 12.5 to 25 mcg per day.
Monitor TSH every 4 weeks until a stable dose is reached and serum TSH is within normal trimester-specific range. Reduce Levothyroxine Sodium Tablets dosage to pre-pregnancy levels immediately after delivery. Monitor serum TSH 4 to 8 weeks postpartum. New onset hypothyroidism (TSH ≥ 10 mIU per liter) 1.6 mcg/kg/day Monitor serum TSH every 4 weeks and adjust Levothyroxine Sodium Tablets dosage until serum TSH is within normal trimester-specific range.
New onset hypothyroidism (TSH < 10 mIU per liter) 1.0 mcg/kg/day TSH Suppression in Well-differentiated Thyroid Cancer in Adult and Pediatric Patients The Levothyroxine Sodium Tablets dosage is based on the target level of TSH suppression for the stage and clinical status of thyroid cancer.
2.4 Monitoring TSH
2.4 Monitoring TSH and/or Thyroxine (T4) Levels Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of Levothyroxine Sodium Tablets may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.
Adults In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dosage. In patients on a stable and appropriate replacement dosage, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient’s clinical status.
Pediatric Patients In patients with congenital hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in pediatric patients as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dosage stabilization until growth is completed.
Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals. The general aim of therapy is to normalize the serum TSH level, TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback.
Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of Levothyroxine Sodium Tablets therapy and/or of the serum TSH to decrease below 20 units per liter within 4 weeks may indicate the patient is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of Levothyroxine Sodium Tablets [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].
Secondary and Tertiary Hypothyroidism Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Levothyroxine Sodium Tablets are indicated in patients from birth to less than 17 years of age: As a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on cognitive development as well as on overall physical growth and maturation. Therefore, initiate Levothyroxine Sodium Tablets therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients [see Warnings and Precautions (5.1)].
Closely monitor infants during the first 2 weeks of Levothyroxine Sodium Tablets therapy for cardiac overload and arrhythmias.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Because of the increased prevalence of cardiovascular disease among the elderly, initiate Levothyroxine Sodium Tablets at less than the full replacement dose [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)]. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly.
Administration
2.1 Important Administration Instructions Administer Levothyroxine Sodium Tablets as a single daily dose, on an empty stomach, one-half to one hour before breakfast. Administer Levothyroxine Sodium Tablets at least 4 hours before or after drugs known to interfere with Levothyroxine Sodium Tablets absorption [see Drug Interactions ( 7.1 )] . Evaluate the need for dosage adjustments when regularly administering within one hour of certain foods that may affect Levothyroxine Sodium Tablets absorption [see Dosage and Administration ( 2.2 and 2.3 ), Drug Interactions ( 7.9 ) and Clinical Pharmacology ( 12.3 )] . Administer Levothyroxine Sodium Tablets to pediatric patients who cannot swallow intact tablets by crushing the tablet, suspending the freshly crushed tablet in a small amount (5 to 10 mL) of water and immediately administering the suspension by spoon or dropper. Ensure the patient ingests the full amount of the suspension. Do not store the suspension. Do not administer in foods that decrease absorption of Levothyroxine Sodium Tablets, such as soybean-based infant formula [see Drug Interactions ( 7.9 )] .
US FDA labelDosage forms
Philippines
- Tablet: 2 mcg, 12.5 mcg, 25 mcg, 50 mcg, 100 mcg, 150 mcg, 300 mcg
Registered products in the Philippines
61 products registered with the Food and Drug Administration (FDA) Philippines list Levothyroxine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products61
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
EltroxinLevothyroxine Sodium | 100 mcg TabletWhite Opaque Polypropylene Bottle (Bottle of 100's) | Rx | Aspen Bad Oldesloe GmbHGermany | Importer: Aspen Philippines, Inc. | DR-9962 | Jun 5, 2027 | |
EltroxinLevothyroxine Sodium | 50 mcg TabletWhite Opaque Polypropylene Bottle of 100's | Rx | Aspen Bad Oldesloe GmbHGermany | Importer: Aspen Philippines, Inc. | DR-9961 | Jun 4, 2027 | |
Eploxin 100Levothyroxine sodium | 100 mcg TabletAlu/Amber PVC Blister Pack x 10’s (Box of 30’s; Box of 50's and Box of 60's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Epione Lifecare Inc.Importer: Despina Pharma, Inc. | DRP-14067-02 | Jun 9, 2028 | |
Eploxin 50Levothyroxine sodium | 50 mcg TabletAlu/Amber Colored PVC Blister Pack x 10’s (Box of 30’s; Box of 50's and Box of 60's) | Rx | Sterile-Gene Life Sciences (P) Ltd.India | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-13157-03 | Dec 12, 2027 | |
EurolevLevothyroxine Sodium | 50 mcg TabletAlu/PVC Blister Pack x 30's (Box of 90's) | Rx | Renata LimitedBangladesh | Euro Generics International Phils., Inc. | DRP-4244 | May 19, 2028 | |
EuthyroxLevothyroxine Sodium | 100 mcg TabletAlu/Alu Blister Pack x 25's (Box of 100's) | Rx | Merck Healthcare KGAAGermany | Merck, Inc. | DRP-15160 | Nov 17, 2026Past listed date | |
EuthyroxLevothyroxine Sodium | 150 mcg TabletAlu/Alu Blister Pack x 25's (Box of 100's) | Rx | Merck Healthcare KGAAGermany | Merck Inc.Importer: Merck, Inc. | DRP-10764 | Nov 17, 2031 | |
EuthyroxLevothyroxine Sodium | 150 mcg TabletAlu/Alu Blister Pack x 25's Box of 100's | Rx | MERCK S.A. DE C.V.Mexico | Importer: Merck, Inc. | DRP-8152 | Aug 14, 2029 | |
EuthyroxLevothyroxine Sodium | 25 mcg TabletAlu/Alu Blister Pack x 25's (Box of 100's) | Rx | Merck Healthcare KGAAGermany | Merck, Inc. | DRP-10772 | Nov 17, 2031 | |
EuthyroxLevothyroxine Sodium | 50 mcg TabletAlu/Alu Blister Pack x 25's (Box of 100's) | Rx | Merck Healthcare KGAAGermany | Merck, Inc. | DRP-10773 | Nov 17, 2026Past listed date | |
Euthyrox 100Levothyroxine Sodium | 100 mcg TabletAlu-Alu Blister Pack x 25's (Box of 100s) | Rx | MERCK S.A. DE C.V.Mexico | Importer: Merck, Inc. | DRP-8153 | Aug 14, 2029 | |
Euthyrox 25Levothyroxine Sodium | 25 mcg TabletAlu/Alu Blister Pack x 25's (Box of 100's) | Rx | MERCK S.A. DE C.V.Mexico | Importer: Merck, Inc. | DRP-8155 | Aug 14, 2029 | |
Euthyrox 50Levothyroxine Sodium | 50 mcg TabletAlu/Alu Blister Pack x 25's (Box of 100's) | Rx | MERCK S.A. DE C.V.Mexico | Importer: Merck, Inc. | DRP-8154 | Aug 14, 2029 | |
ForhypoLevothyroxine (as sodium) | 100 mcg TabletAmber Glass Bottle x 100's (Box of 1's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Alternative Platform Exchange, Inc.Importer: Lloyd Laboratories, Inc. | DRP-7271-03 | May 20, 2029 | |
ForhypoLevothyroxine (as Sodium) | 25 mcg TabletAmber Glass Bottle x 100's (Box of 1's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Alternative Platform Exchange, Inc.Importer: Lloyd Laboratories, Inc. | DRP-7269-02 | May 26, 2029 | |
ForhypoLevothyroxine (as Sodium) | 50 mcg TabletAmber Glass Bottle x 100's (Box of 1's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Alternative Platform Exchange, Inc.Importer: Lloyd Laboratories, Inc. | DRP-7270-03 | Jul 30, 2029 | |
LevopremixLevothyroxine sodium | 100 mcg TabletAlu / Amber PVC Blister Pack x 10's (Box of 50's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Premier Pharmaceuticals Marketing Corp.Importer: Despina Pharma, Inc. | DRP-14067-04 | Jun 9, 2028 | |
LevostratLevothyroxine Sodium | 100 mcg TabletAlu/Amber PVC Blister Pack x 10’s (Box of 30's, 50's, 60's and 100's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Bio-Strata Pharmaceuticals, Inc.Importer: Despina Pharma, Inc. | DRP-14067-07 | Jun 9, 2028 | |
LevostratLevothyroxine sodium | 50 mcg TabletAlu/Amber Colored PVC Blister Pack x 10's (Box of 50's) | Rx | Sterile-Gene Life Sciences (P) Ltd.India | Bio-Strata Pharmaceuticals, Inc.Importer: Despina Pharma, Inc. | DRP-13157-01 | Dec 12, 2027 | |
LevothyrogenLevothyroxine (as sodium) | 100 mcg TabletAmber Glass Bottle x 100's (Box of 1's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Medchoice Distribution, Inc.Importer: Lloyd Laboratories, Inc. | DRP-7271-02 | May 20, 2029 | |
LevothyrogenLevothyroxine (as sodium) | 25 mcg TabletAmber Glass Bottle x 100's (Box of 1's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Medchoice Distribution, Inc.Importer: Lloyd Laboratories, Inc. | DRP-7269-01 | May 26, 2029 | |
LevothyrogenLevothyroxine (as sodium) | 50 mcg TabletAmber Glass Bottle x 100's (Box of 1's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Medchoice Distribution, Inc.Importer: Lloyd Laboratories, Inc. | DRP-7270-02 | Jul 30, 2029 | |
Levotris 25Levothyroxine Sodium | 2 mcg TabletAlu/Alu Blister pack x 10's (Box of 30's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-18318 | Jun 11, 2031 | |
NoneLevothyroxine Sodium | 50 mcg TabletAlu/PVC Blister pack x 30's (Box of 90's) | Rx | Renata LimitedBangladesh | TGP Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-4244-01 | May 19, 2028 | |
Novathroxine 100Levothyroxine sodium | 100 mcg TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's, 50's and 100's) | Rx | Acme Generics LLP.India | Medinova Pharmaceutical Inc. | DRP-17375 | Nov 25, 2030 | |
Novathroxine 150Levothyroxine Sodium | 150 mcg TabletAlu-Alu Blister Pack x 10's (Box of 10's, 30's 50's and 100's) | Rx | Acme Generics LLP.India | Medinova Pharmaceutical Inc. | DRP-18616 | Aug 5, 2031 | |
SaphvothyroxLevothyroxine sodium | 25 mcg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Health Biotech Ltd.India | Nelpa Lifesciences, Inc. | DRP-17210 | Oct 20, 2030 | |
SaphvothyroxLevothyroxine Sodium | 50 mcg TabletAlu/Alu Blister Pack of 10's (Box of 50's) | Rx | Health Biotech Ltd.India | Nelpa Lifesciences Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-18627 | Aug 12, 2031 | |
TFourLevothyroxine (as Sodium) | 100 mcg TabletAmber Glass Bottle x 100's (Box of 1's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Unilab Inc.Importer: Lloyd Laboratories, Inc. | DRP-7271-01 | May 20, 2029 | |
TFourLevothyroxine (as sodium) | 50 mcg TabletAmber Glass Bottle x 100's (Box of 1's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | UNILAB, Inc.Importer: Lloyd Laboratories, Inc. | DRP-7270-01 | Jul 30, 2029 | |
Throxinov 100Levothyroxine Sodium | 100 mcg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Ratnataris Pharmaceuticals Private LimitedIndia | Medinova Pharmaceutical Inc.. | DRP-17934 | Apr 13, 2031 | |
Throxinov 25Levothyroxine Sodium | 25 mcg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | Medinova Pharmaceutical Inc.. | DRP-17935 | Apr 13, 2031 | |
ThydinLevothyroxine Sodium | 100 mcg TabletAlu/PVDC White Opaque Blister Pack x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | Trader: Medchoice Endocrine Group, Inc. | DRP-7793 | Feb 10, 2031 | |
ThydinLevothyroxine Sodium | 12.5 mcg TabletAlu/White Opaque PVDC Blister Pack x 10's Box of 100's | Rx | Sydenham Laboratories, Inc.Philippines | Trader: Medchoice Endocrine Group, Inc. | DRP-7790 | Jan 21, 2030 | |
ThydinLevothyroxine Sodium | 150 mcg TabletAlu/PVDC White Opaque Blister Pack x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | Trader: Medchoice Endocrine Group, Inc. | DRP-7794 | Jan 21, 2030 | |
ThydinLevothyroxine Sodium | 25 mcg TabletAlu/PVDC White Opaque Blister Pack x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | Trader: Medchoice Endocrine Group, Inc. | DRP-7791 | Dec 18, 2029 | |
ThydinLevothyroxine Sodium | 50 mcg TabletAlu/PVDC White Opaque Blister Pack x 10's Box of 100's; Alu/PVDC White Opaque Blister Pack x 10's Box of 60's in Twin Blister Pack | Rx | Sydenham Laboratories, Inc.Philippines | Trader: Medchoice Endocrine Group, Inc. | DRP-7792 | Jan 22, 2030 | |
Thyranex 100Levothyroxine sodium | 100 mcg TabletAlu/Amber PVC Blister Pack x 10's (Box of 50's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Radbuster Inc.Importer: Despina Pharma, Inc. | DRP-14067-03 | Jun 9, 2028 | |
Thyranex 50Levothyroxine sodium | 50 mcg TabletAlu/Amber Colored PVC Blister Pack x 10's (Box of 50's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Radbuster Inc.Importer: Despina Pharma, Inc. | DRP-13157-04 | Dec 12, 2027 | |
Thyres 100Levothyroxine sodium | 100 mcg TabletAlu/Amber PVC Blister Pack x 10's (Box of 50's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Despina Pharma, Inc. | DRP-14067 | Jun 9, 2028 | |
Thyres 50Levothyroxine sodium | 50 mcg TabletAlu/Amber Colored PVC Blister Pack X 10's (Box of 50's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Despina Pharma, Inc. | DRP-13157 | Dec 12, 2027 | |
ThyrofixLevothyroxine Sodium (as hydrate) | 100 mcg TabletAlu/Clear PVC/TE/PVDC blister pack x 10's (Box of 30's) | Rx | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories SAGreece | Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc. | DRP-14834 | Jan 18, 2029 | |
ThyrofixLevothyroxine Sodium (as hydrate) | 25 mcg TabletAlu/Clear PVC/TE/PVDC blister pack X 10's (Box of 30's) | Rx | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories SAGreece | Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc. | DRP-14261 | Aug 4, 2028 | |
ThyrofixLevothyroxine Sodium (as hydrate) | 50 mcg TabletAlu/Clear PVC/TE/PVDC blister pack X 10's (Box of 30's) | Rx | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories SAGreece | Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc. | DRP-14835 | Jan 18, 2029 | |
THYRONIX 100Levothyroxine sodium | 100 mcg TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's, 50's and 100's) | Rx | Acme Generics Private LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-17375-01 | Nov 25, 2030 | |
Thyronix 50Levothyroxine sodium | 50 mcg TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's, 50's and 100's) | Rx | Acme Generics Private LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-17380-01 | Dec 4, 2030 | |
ThyrotechLevothyroxine sodium | 100 mcg TabletAlu / Amber PVC Blister Pack x 10's (Box of 100's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Despina Pharma, Inc. | DRP-14067-06 | Jun 9, 2028 | |
ThyrotechLevothyroxine sodium | 50 mcg TabletAlu/Amber Colored PVC Blister Pack x 10's (Box of 100's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Despina Pharma, Inc. | DRP-13157-06 | Dec 12, 2027 | |
Thyrox 300Levothyroxine sodium | 300 mcg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Macleods Pharmaceuticals LimitedIndia | Macleods Pharmaceuticals Philippines, Inc. | DR-XY49433 | Jul 1, 2030 | |
Thyrox 50Levothyroxine sodium | 50 mcg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Macleods Pharmaceuticals LimitedIndia | Macleods Pharmaceuticals Philippines, Inc. | DR-XY49434 | Jul 1, 2030 | |
ThyroxilLevothyroxine Sodium | 100 mcg TabletAlu/Amber PVC Blister Pack x 10's (Box of 50's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | The Cathay Yss Distributors Co., Inc.Importer: Despina Pharma Inc. | DRP-14067-01 | Jun 9, 2028 | |
ThyroxilLevothyroxine sodium | 50 mcg TabletAlu/Amber Colored PVC Blister Pack x 10's (Box of 50's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | The Cathay YSS Distributors Co., Inc.Importer: Despina Pharma, Inc. | DRP-13157-02 | Dec 12, 2027 | |
Thyvex 100Levothyroxine sodium | 100 mcg TabletAlu/Amber PVC Blister Pack x 10's (Box of 50's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | VE Pharma Inc.Importer: Despina Pharma Inc. | DRP-14067-05 | Jun 9, 2028 | |
Thyvex 50Levothyroxine sodium | 50 mcg TabletAlu/Amber Colored PVC Blister Pack x 10's (Box of 50's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | VE Pharma Inc.Importer: Despina Pharma Inc. | DRP-13157-05 | Dec 12, 2027 | |
Thyvex-100Levothyroxine Sodium | 100 mcg TabletAlu/Alu Blister Pack x 10’s (Box of 50’s) | Rx | West Coast Pharmaceutical Works Ltd.India | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY10141 | Aug 5, 2031 | |
Thyvex-50Levothyroxine Sodium | 50 mcg TabletAlu/Alu Blister Pack x 10’s (Box of 50’s) | Rx | West-Coast Pharmaceuticals Works Ltd.India | Ve Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY10142 | Aug 5, 2031 | |
ZalianaLevothyroxine (as Sodium) | 100 mcg TabletAmber Glass Bottle x 100's (Box of 1's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Innogen Pharmaceuticals, Inc.Importer: Lloyd Laboratories, Inc. | DRP-7271 | May 20, 2029 | |
ZalianaLevothyroxine (as sodium) | 25 mcg TabletAmber Glass Bottle x 100's (Box of 1's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Innogen Pharmaceuticals, Inc.Importer: Lloyd Laboratories, Inc. | DRP-7269 | May 26, 2029 | |
ZalianaLevothyroxine (as Sodium) | 50 mcg TabletAmber Glass Bottle x 100's (Box of 1's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Innogen Pharmaceuticals, Inc.Importer: Lloyd Laboratories, Inc. | DRP-7270 | Jul 30, 2029 | |
(no brand name)Levothyroxine Sodium | 100 mcg TabletHigh Density Polyetyhlene (HDPE) Bottle (Bottle of 90's) | Rx | Intas Pharmaceutical LimitedIndia | RiteMED Phils., Inc. | DRP-18778 | Sep 3, 2031 | |
(no brand name)Levothyroxine Sodium | 150 mcg TabletHigh Density Polyethylene (HDPE) Bottle (Bottle of 90's) | Rx | Intas Pharmaceutical LimitedIndia | RiteMED Phils., Inc. | DRP-18777 | Sep 3, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Levothyroxine Sodium Tablets, in the shape of caplet, are available as follows (Table 4): Table 4. Levothyroxine Sodium Tablets Tablet Strengths and Identifying Features Tablet Strength Tablet Color Tablet Markings 25 mcg Orange "T|4" and "25" 50 mcg White "T|4" and "50" 75 mcg Violet "T|4" and "75" 88 mcg Mint Green "T|4" and "88" 100 mcg Yellow "T|4" and "100" 112 mcg Rose "T|4" and "112" 125 mcg Brown "T|4" and "125" 137 mcg Deep Blue "T|4" and "137" 150 mcg Light Blue "T|4" and "150" 175 mcg Lilac "T|4" and "175" 200 mcg Pink "T|4" and "200" 300 mcg Green "T|4" and "300" Tablets: 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, and 300 mcg (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Serious risks related to overtreatment or undertreatment with Levothyroxine Sodium Tablets: Titrate the dose of Levothyroxine Sodium Tablets carefully and monitor response to titration. (5.1)
- Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate Levothyroxine Sodium Tablets at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation. (2.3, 5.2, 8.5)
- Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma. (5.3)
- Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of Levothyroxine Sodium Tablets treatment. (5.4)
- Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy. (5.5)
- Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone resorption and decrease bone mineral density. Give the lowest effective dose. (5.6)
5.1 Serious Risks Related to Overtreatment or Undertreatment with Levothyroxine Sodium Tablets
5.1 Serious Risks Related to Overtreatment or Undertreatment with Levothyroxine Sodium Tablets Levothyroxine Sodium Tablets have a narrow therapeutic index. Overtreatment or undertreatment with Levothyroxine Sodium Tablets may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, gastrointestinal function, and glucose and lipid metabolism in adult or pediatric patients.
In pediatric patients with congenital and acquired hypothyroidism, undertreatment may adversely affect cognitive development and linear growth, and overtreatment is associated with craniosynostosis and acceleration of bone age [see Use in Specific Populations (8.4)]. Titrate the dose of Levothyroxine Sodium Tablets carefully and monitor response to titration to avoid these effects [see Dosage and Administration (2.4)].
Consider the potential for food or drug interactions and adjust the administration or dosage of Levothyroxine Sodium Tablets as needed [see Dosage and Administration (2.1), Drug Interactions (7.1, 7.9), and Clinical Pharmacology (12.3)].
5.2 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular…
5.2 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease Overtreatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate Levothyroxine Sodium Tablets therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease [see Dosage and Administration (2.3) and Use in Specific Populations (8.5)].
Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive Levothyroxine Sodium Tablets therapy. Monitor patients receiving concomitant Levothyroxine Sodium Tablets and sympathomimetic agents for signs and symptoms of coronary insufficiency. If cardiac symptoms develop or worsen, reduce the Levothyroxine Sodium Tablets dose or withhold for one week and restart at a lower dose.
5.3 Myxedema Coma
5.3 Myxedema Coma Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.
5.4 Acute Adrenal Crisis in Patients with Concomitant
5.4 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with Levothyroxine Sodium Tablets [see Contraindications (4)].
5.5 Worsening of Diabetic Control
5.5 Worsening of Diabetic Control Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing Levothyroxine Sodium Tablets [see Drug Interactions (7.2)].
5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement
5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels.
Administer the minimum dose of Levothyroxine Sodium Tablets that achieves the desired clinical and biochemical response to mitigate this risk.
Drug interactions
See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium Tablets. (7)
7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics
7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics Many drugs can exert effects on thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium Tablets (Tables 5 to 8). Table 5.
Drugs That May Decrease T4 Absorption (Hypothyroidism) Potential impact: Concurrent use may reduce the efficacy of Levothyroxine Sodium Tablets by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Drug or Drug Class Effect Phosphate Binders (e.g., calcium carbonate, ferrous sulfate, sevelamer, lanthanum) Phosphate binders may bind to levothyroxine.
Administer Levothyroxine Sodium Tablets at least 4 hours apart from these agents. Orlistat Monitor patients treated concomitantly with orlistat and Levothyroxine Sodium Tablets for changes in thyroid function. Bile Acid Sequestrants (e.g., colesevelam, cholestyramine, colestipol) Ion Exchange Resins (e.g., Kayexalate) Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption.
Administer Levothyroxine Sodium Tablets at least 4 hours prior to these drugs or monitor TSH levels. Proton Pump Inhibitors Sucralfate Antacids (e.g., aluminum & magnesium hydroxides, simethicone) Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption.
Monitor patients appropriately. Table 6. Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism) Drug or Drug Class Effect Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin / Methadone 5-Fluorouracil Mitotane Tamoxifen These drugs may increase serum thyroxine-binding globulin (TBG) concentration.
Androgens / Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid These drugs may decrease serum TBG concentration. Potential impact (below): Administration of these agents with Levothyroxine Sodium Tablets results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations.
Salicylates (greater than 2 g/day) Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%. Other drugs: Carbamazepine Furosemide (greater than 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement.
Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid.
Closely monitor thyroid hormone parameters. Table 7. Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism) Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased Levothyroxine Sodium Tablets requirements.
Drug or Drug Class Effect Phenobarbital Rifampin Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5'-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism.
Rifampin has been shown to accelerate the metabolism of levothyroxine. Table 8. Drugs That May Decrease Conversion of T4 to T3 Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased.
Drug or Drug Class Effect Beta-adrenergic antagonists (e.g., Propranolol greater than 160 mg/day) In patients treated with large doses of propranolol (greater than 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when a hypothyroid patient is converted to the euthyroid state.
Glucocorticoids (e.g., Dexamethasone greater than or equal to 4 mg/day) Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above).
Other drugs: Amiodarone Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients.
7.2 Antidiabetic Therapy Addition of Levothyroxine Sodium
7.2 Antidiabetic Therapy Addition of Levothyroxine Sodium Tablets therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued [see Warnings and Precautions (5.5)].
7.3 Oral Anticoagulants
7.3 Oral Anticoagulants Levothyroxine Sodium Tablets increase the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the Levothyroxine Sodium Tablets dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.
7.4 Digitalis Glycosides
7.4 Digitalis Glycosides Levothyroxine Sodium Tablets may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may decrease when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.
7.5 Antidepressant Therapy
7.5 Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and Levothyroxine Sodium Tablets may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation.
Levothyroxine Sodium Tablets may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on Levothyroxine Sodium Tablets may result in increased Levothyroxine Sodium Tablets requirements.
7.6 Ketamine
7.6 Ketamine Concurrent use of ketamine and Levothyroxine Sodium Tablets may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.
7.7 Sympathomimetics
7.7 Sympathomimetics Concurrent use of sympathomimetics and Levothyroxine Sodium Tablets may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.
7.8 Tyrosine-Kinase Inhibitors
7.8 Tyrosine-Kinase Inhibitors Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients.
7.9 Drug-Food Interactions
7.9 Drug-Food Interactions Consumption of certain foods may affect Levothyroxine Sodium Tablets absorption thereby necessitating adjustments in dosing [see Dosage and Administration (2.1)]. Soybean flour, cottonseed meal, walnuts, and dietary fiber may bind and decrease the absorption of Levothyroxine Sodium Tablets from the gastrointestinal tract.
Grapefruit juice may delay the absorption of levothyroxine and reduce its bioavailability.
7.10 Drug-Laboratory Test Interactions
7.10 Drug-Laboratory Test Interactions Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free-T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentration.
Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens, and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS Adverse reactions associated with Levothyroxine Sodium Tablets therapy are primarily those of hyperthyroidism due to therapeutic overdosage [see Warnings and Precautions (5) and Overdosage (10)]. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia Musculoskeletal: tremors, muscle weakness, muscle spasm Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests Dermatologic: hair loss, flushing, rash Endocrine: decreased bone mineral density Reproductive: menstrual irregularities, impaired fertility Seizures have been reported rarely with the institution of levothyroxine therapy.
Adverse Reactions in Pediatric Patients Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants who have not undergone complete closure of the fontanelles, and in premature closure of the epiphyses in pediatric patients still experiencing growth with resultant compromised adult height.
Hypersensitivity Reactions Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness, and wheezing.
Hypersensitivity to levothyroxine itself is not known to occur. Adverse reactions associated with Levothyroxine Sodium Tablets therapy are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash.
(6) To report SUSPECTED ADVERSE REACTIONS, contact Alvogen, Inc. at 1-866-770-3024 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary The clinical experience, including data from postmarketing studies, in pregnant women treated with oral levothyroxine to maintain euthyroid state have not reported increased rates of major birth defects, miscarriages, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy.
Since TSH levels may increase during pregnancy, TSH should be monitored and Levothyroxine Sodium Tablets dosage adjusted during pregnancy (see Clinical Considerations). Animal reproductive studies have not been conducted with levothyroxine sodium. Levothyroxine Sodium Tablets should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development.
Dose Adjustments During Pregnancy and the Postpartum Period Pregnancy may increase Levothyroxine Sodium Tablets requirements. Serum TSH levels should be monitored and the Levothyroxine Sodium Tablets dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the Levothyroxine Sodium Tablets dosage should return to the pre-pregnancy dose immediately after delivery [see Dosage and Administration (2.3)].
Mechanism of action
12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present.
Pharmacokinetics
The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3.
Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.
Excretion Thyroid hormones are primarily eliminated by the kidneys.
Urinary excretion of T4 decreases with age.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the Levothyroxine Sodium Tablets dose is absorbed from the jejunum and upper ileum. The relative bioavailability of Levothyroxine Sodium Tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 94%.
T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption [see Drug Interactions (7)]. Distribution Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone.
The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins [see Drug Interactions (7)].
Thyroid hormones do not readily cross the placental barrier [see Use in Specific Populations (8.1)]. Elimination Metabolism T4 is slowly eliminated (Table 10). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination.
The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine.
Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation. Excretion Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces.
Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age. Table 10. Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients * Includes TBG, TBPA, and TBA ** 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism Hormone Ratio in Thyroglobulin Biologic Potency t 1/2 (days) Protein Binding (%)* Levothyroxine (T4) 10 - 20 1 6-7** 99.96 Liothyronine (T3) 1 4 ≤ 2 99.5
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Levothyroxine 50mcg Tablet | ₱2.50–₱3.85Reference ₱3.44 | per tablet | DPRI procurement range |
| Levothyroxine 100 mcg Tablet | ₱5.50–₱10.00Reference ₱6.47 | per tablet | DPRI procurement range |
| Levothyroxine 150 mcg Tablet | ₱10.20–₱10.89Reference ₱10.20 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Levothyroxine (as sodium/anhydrous sodium) |
| PNF listing | Oral: 50 mcg, 100 mcg and 150 mcg tablet |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. levothyroxine sodium · Alvogen, Inc. [US FDA-approved label, version 10, September 15, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ddcaec1-a58f-340b-9bc1-bbe048b8c885
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
